[
    [
        {
            "time": "",
            "original_text": "年报解读|健民集团高增长隐忧：研发投入缩水销售费用大增",
            "features": {
                "keywords": [
                    "健民集团",
                    "高增长",
                    "研发投入",
                    "缩水",
                    "销售费用",
                    "大增"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "年报解读|健民集团高增长隐忧：研发投入缩水销售费用大增",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业周报：CXO、医疗服务、生物制品等板块预计Q1高增长",
            "features": {
                "keywords": [
                    "医药生物",
                    "CXO",
                    "医疗服务",
                    "生物制品",
                    "Q1",
                    "高增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物制品"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业周报：CXO、医疗服务、生物制品等板块预计Q1高增长",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "片仔癀：《片仔癀调控肿瘤细胞凋亡与增殖的途径》是国家自然科学基金项目，与公司无关",
            "features": {
                "keywords": [
                    "片仔癀",
                    "肿瘤细胞",
                    "凋亡",
                    "增殖",
                    "国家自然科学基金",
                    "无关"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "片仔癀：《片仔癀调控肿瘤细胞凋亡与增殖的途径》是国家自然科学基金项目，与公司无关",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]